- Home
- TARA
TARA
Protara Therapeutics Inc.
as 05-09-2025 3:43pm EST
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $20.60 | AVG Volume (30 days): | 544.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.63 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.59 - $10.48 | Next Earning Date: | 05-08-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Protara Therapeutics Inc. (TARA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Zummo Jacqueline | TARA | Chf Scientific Operations Off | Mar 26 '25 | Sell | $4.53 | 21,224 | $96,144.72 | 98,861 |
Latest Protara Therapeutics Inc. News
TARA Breaking Stock News: Dive into TARA Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
8 days ago
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
13 days ago
Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
GlobeNewswire
16 days ago
Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025
GlobeNewswire
24 days ago
Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer
GlobeNewswire
a month ago
Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting
GlobeNewswire
2 months ago
Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support
Simply Wall St.
2 months ago
Protara Therapeutics (NASDAQ:TARA) Is In A Good Position To Deliver On Growth Plans
Compare TARA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TARA Protara Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.